BPX-201 Vaccine for Chemotherapy-Naïve mCRPC

Clinical Pearls

Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncology—Baylor Charles A. Sammons Cancer Center, discusses a phase I study of BPX-201 vaccine plus AP1903 for chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

• BPX-201 is novel, second-generation, autologous antigen presenting cell-based vaccine.
• In a previous phase I trial, this has proven to be a potent approach to vaccination against prostate cancer.
• There is hope that this approach will lead to both survival benefit and real-time benefit in the form of tumor responses and PSA reductions.
• To date, 6 patients have been enrolled in the trial and no dose-limiting toxicities have been observed.

<<<

Back to "Immunotherapy News from ASCO"